Literature DB >> 9720093

Visceral leishmaniasis: a lingual presentation in a patient with HIV infection.

T Vázquez-Piñeiro1, J M Fernández Alvarez, J C Gonzalo Lafuente, J Cano, M Gimeno, J Berenguer.   

Abstract

The term leishmaniasis covers a series of illnesses caused by the protozoan Leishmania; depending on the patient's immune response, the particular species of the protozoan, and the geography, the condition may manifest itself as cutaneous, mucocutaneous, or visceral disease. Visceral leishmaniasis has often been found as a co-infection associated with the human immunodeficiency virus, particularly in the region of the western Mediterranean. We report the case of an HIV-infected patient with a history of treated laryngeal leishmaniasis who subsequently appeared for treatment with a tumorous lesion on the dorsum of the tongue that was caused by Leishmania infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9720093     DOI: 10.1016/s1079-2104(98)90122-6

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  4 in total

1.  Homology modeling and atomic level binding study of Leishmania MAPK with inhibitors.

Authors:  Mahendra Awale; Vivek Kumar; Parameswaran Saravanan; C Gopi Mohan
Journal:  J Mol Model       Date:  2009-08-02       Impact factor: 1.810

Review 2.  PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.

Authors:  Eduard E Zijlstra
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

3.  Lingual Leishmaniasis Presenting to Maxillofacial Surgery in UK with Successful Treatment with Miltefosine.

Authors:  K Kassam; R Davidson; P J Tadrous; M Kumar
Journal:  Case Rep Med       Date:  2013-09-30

4.  Control of Cutaneous Leishmaniasis Using Geographic Information Systems from 2010 to 2014 in Khuzestan Province, Iran.

Authors:  Mojdeh Ostad; Sadegh Shirian; Fatemeh Pishro; Tahereh Abbasi; Armin Ai; Farideh Azimi
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.